Article
Ilhan Omar Raid Records To Be Made Public As Soon As Monday
Ilhan Omar Raid Records To Be Made Public As Soon As Monday
Chief US District Judge James Boasberg ruled Tuesday that parts of the sealed records from the federal search of Rep. Ilhan Omar's Washington home will be released with redactions, possibly as soon as Monday, while the 67-page affidavit laying out the government's case stays under seal.
Rep. Ilhan Omar Daniel Heuer/Bloomberg News
Prosecutors have until Friday, Nov. 20, to propose redactions, including to the search warrant docket sheet, and the court will publish the redacted versions no earlier than 5...
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
May 18, 2026 / Dave DeCamp
Cuba’s President Warns That US Attack Will Cause ‘Bloodbath’
Cuban President Miguel Diaz-Canel said on Monday that any US attack on Cuba would cause a “bloodbath,” a warning that comes as US officials are setting up pretexts for a potential war on the island nation. “The threats of military aggression against [Cuba] from the world’s greatest power are well-known,” Diaz-Canel wrote on X. “The […]
Read more
Apr 10, 2026 / Tyler Durden
"Terrifies Billionaire Class": Pro-China Party Of Socialism & Liberation Plans General Strike On U.S. Economy
Aug 19, 2026 / Tyler Durden
Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success
Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success
Moderna's shares soared as much as 83% in premarket trading in New York after its personalized cancer vaccine, developed in collaboration with Merck & Co., reduced the risk of melanoma returning in a large, late-stage trial. The result marks the first positive Phase 3 trial for a personalized cancer vaccine by any company.
The study met its primary endpoint by showing that the cancer vaccine, called intismeran autogene, combined with Merck's blockbuster immunotherapy Keytruda, improved recurrence-free survival compared...
Read more




